|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: April 2024
Volume 9 | Issue 4
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 95
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | Formulation and Evaluation of Pharmacosomal Drug Delivery System Of Metformin |
| Authors Name: | Dr. Sachin Shivling Bhusari , Aarti Raju Popalghat , Dr.Pravin.S.Wakte |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_200541
|
| Published Paper Id: | IJNRD2306633 |
| Published In: | Volume 8 Issue 6, June-2023 |
| DOI: | |
| Abstract: | This research paper presents a comprehensive investigation into the development, validation, and evaluation of phosphotidylcholine-based pharmacosomes for the efficient delivery of Metformin Hal. Pharmacosomes, emerging as vesicular drug delivery systems, offer tremendous potential to overcome the limitations associated with conventional drug formulations. Metformin HCl, a widely prescribed anti-diabetic drug, often faces challenges in solubility and bioavailability. By utilizing phosphotidylcholine as the primary phospholipid, this study aims to optimize the formulation method, validate its robustness, and evaluate the performance and characteristics of the developed pharmacosomes. Through meticulous selection of phosphotidylcholine and complementary recipients, the formulation parameters, including the drug-to-lipid ratio and lipid-to-surfactant ratio, were optimized to achieve superior drug entrapment efficiency and enhanced stability. Various techniques such as thin-film hydration and solvent evaporation were employed for pharmacosomes preparation, yielding well-defined structures characterized by their size, morphology, and zeta potential. The developed method was subjected to rigorous validation according to regulatory guidelines, including specificity, linearity, precision, accuracy, and robustness assessments. The limit of detection (LOD) and limit of quantification (LOQ) were determined, ensuring sensitivity for future pharmacokinetic studies. Statistical analysis of the validation data confirmed the reliability and reproducibility of the method. Physicochemical characterization revealed the favourable attributes of the phosphotidylcholine-based pharmacosomes, including a narrow particle size distribution, optimal surface charge, and improved drug loading efficiency. Furthermore, the drug release kinetics demonstrated sustained and controlled release profiles, indicating the potential for prolonged therapeutic effects. The stability assessment, encompassing both physical and chemical stability studies, confirmed the long-term viability of the pharmacosomes. In vitro and/or in vivo evaluation of pharmacodynamic and pharmacokinetic parameters further demonstrated the enhanced performance of the phosphotidylcholine-based pharmacosomes in comparison to conventional formulations. This research establishes phosphotidylcholine-based pharmacosomes as a promising and efficient strategy for delivering Metformin Hal. The findings provide valuable insights into the formulation and application of pharmacosomes, highlighting their potential for improving therapeutic outcomes in diabetes management. |
| Keywords: | Pharmacosomes, Metformin Hal, phosphotidylcholine, formulation optimization, method validation, sustained release, drug delivery, and diabetes management |
| Cite Article: | "Formulation and Evaluation of Pharmacosomal Drug Delivery System Of Metformin", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 6, page no.g279-g302, June-2023, Available :http://www.ijnrd.org/papers/IJNRD2306633.pdf |
| Downloads: | 000118767 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2306633 Registration ID: 200541 Published In: Volume 8 Issue 6, June-2023 DOI (Digital Object Identifier): Page No: g279-g302 Country: Aurangabad, Maharashtra, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2306633 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2306633 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn